DUTCH Test Interpretation for Functional Medicine Practitioners: A Clinical Reference for Hormone Panel Analysis

DUTCH test interpretation is where functional endocrinology's interpretive complexity concentrates. A DUTCH Complete panel delivers nearly 50 individual markers across six categories — cortisol patterns, sex hormone metabolites, estrogen hydroxylation metabolites, melatonin, neurotransmitter precursors, and organic acid data — all of which need to be synthesized into a coherent clinical picture before a treatment protocol can follow. For practitioners ordering the DUTCH hormone test routinely, interpreting DUTCH test results is not a passive reporting exercise — it is the central bottleneck in complex endocrine cases.

This DUTCH test for practitioners reference organizes interpretation in the sequence the markers actually demand — beginning with the stress axis, then moving to sex hormones, then to OAT markers — rather than following the report's default layout. Interpreting DUTCH test results in this order prevents the most common interpretive error: attributing estrogen dominance symptoms to the sex hormone axis when the cortisol axis is the primary driver.

---

What the DUTCH test measures — and the interpretation sequence that matters

The DUTCH Complete panel (dried urine, LC-MS/MS methodology) is the most comprehensive adrenal hormone testing platform in routine clinical use. It captures six categories of data in a single collection — more than any serum hormone panel interpretation can provide:

• Free cortisol at four diurnal time points (morning, noon, evening, night)
• Cortisol metabolites (THF, THE, a-THF) reflecting clearance rate
• Sex hormone metabolites — estrogens, progesterone metabolite (pregnanediol), androgens, DHEA-S
• Estrogen hydroxylation metabolites — 2-OHE1, 4-OHE1, 16α-OHE1, and methylation byproducts (2-MeOE1)
• Melatonin (6-OHMS, the primary urinary melatonin metabolite)
• Organic acid markers — neurotransmitter metabolites, B vitamin status markers, oxidative stress (8-OHdG), and gut dysbiosis indicators

The interpretive error most practitioners make is reading the report in the order it is printed. Adrenal output governs downstream hormone synthesis, neurotransmitter precursor availability, and estrogen clearance. If you evaluate estrogen metabolites before understanding the cortisol picture, you will misattribute downstream effects to the wrong root cause.

Cortisol pattern and HPA axis assessment (starting point)

The cortisol diurnal curve is the foundation. Four clinical patterns dominate in practice:

Pattern	Finding	Implication
Flat	Low all four time points	HPA axis exhaustion — adrenal output insufficient
Elevated	High all four time points	Chronic stress response, HPA hyperactivation
Frozen	Normal AM, crashes by noon	Lost diurnal rhythm, pre-burnout phase
Chaotic	No predictable pattern	Severe dysregulation — post-viral, post-trauma, or multi-stressor context

Cortisol metabolites (THF, THE, a-THF) add a second layer. Normal or elevated free cortisol with low metabolites points to impaired hepatic clearance; elevated metabolites with normal free cortisol indicates rapid clearance driving demand. Neither pattern appears on serum.

The cortisol:DHEA-S ratio follows directly from the cortisol assessment. A high ratio — elevated cortisol with depleted DHEA-S — indicates a catabolic, cortisol-dominant axis with insufficient anabolic reserve. This is the burnout signature before symptoms become unmistakable.

Sex hormone pathway mapping (estrogen, progesterone, testosterone metabolites)

Once the stress axis is clear, evaluate estrogen in three steps:

Step 1 — Identify the hydroxylation pattern. DUTCH measures three estrogen metabolite streams from hepatic Phase 1 hydroxylation: 2-OHE1 (protective, weakly estrogenic), 4-OHE1 (genotoxic, associated with DNA adduct formation), and 16α-OHE1 (proliferative). The 2/16 ratio (2-OHE1 ÷ 16α-OHE1; optimal ≥ 1.0, ideally ≥ 2.0) indicates how favorably the body routes estrogen. [Muti P et al. Epidemiology. 2000;11(6):635–40. PMID 11055622; clinical thresholds per Precision Analytical DUTCH Interpretation Guide]

Step 2 — Assess COMT methylation throughput. Compare 2-OHE1 (unmethylated) to 2-MeOE1 (methylated). A low 2-MeOE1 relative to 2-OHE1 indicates impaired COMT-mediated Phase 2 methylation — not an estrogen production problem. Treatment priority shifts from DIM to fixing methylation cofactors first: methylcobalamin, L-5-MTHF, riboflavin, magnesium. [Dawling S et al. Cancer Res. 2001;61(18):6716–22. PMID 11559542]

Step 3 — Evaluate pregnanediol and testosterone metabolites. Low pregnanediol in a cycling patient indicates luteal phase deficiency or anovulation — often from HPA-driven pregnenolone steal. For male patients, testosterone metabolite pattern (androsterone, etiocholanolone, 5α-androstanediol) distinguishes adrenal-origin androgen depletion from primary gonadal failure, and elevated 5α-androstanediol signals high 5α-reductase activity relevant to androgenic alopecia and PCOS presentations.

Melatonin and sleep-wake signaling

DUTCH Complete measures 6-hydroxymelatonin sulfate (6-OHMS), the primary urinary melatonin metabolite. Low 6-OHMS in a patient with sleep-onset or sleep-maintenance complaints confirms melatonin insufficiency rather than requiring an inference.

The combination that changes treatment most is elevated nocturnal cortisol plus low 6-OHMS — classic cortisol-melatonin antagonism. Addressing melatonin before the nocturnal cortisol driver will produce partial and temporary results at best. The correct sequence is cortisol reduction first (phosphatidylserine, parasympathetic activation, light discipline), then melatonin support (0.5–3mg, 2 hours pre-sleep).

Organic acid markers — B vitamin sufficiency and neurotransmitter precursors

The OAT section of DUTCH Complete contextualizes everything above. Key markers:

• 5-HIAA: Serotonin turnover. Low 5-HIAA with intact VMA distinguishes serotonin depletion from generalized neurological stress.
• VMA: Epinephrine and norepinephrine turnover. Elevated VMA signals catecholamine excess — sympathetic overdrive that predicts poor sleep, elevated anxiety, and often the 3 AM cortisol rebound.
• HVA: Dopamine turnover. Low HVA in combination with low 5-HIAA indicates a neurotransmitter depletion pattern requiring precursor support (tyrosine, tryptophan) rather than cognitive or behavioral interventions alone.
• Kynurenic acid / xanthurenic acid: Elevated xanthurenic acid is a reliable B6 deficiency marker and also indicates kynurenine pathway activation — clinically relevant in refractory depression and chronic inflammatory presentations.
• 8-OHdG: Oxidative DNA damage. Elevated 8-OHdG flags systemic oxidative burden and often connects a hormone picture (particularly elevated 4-OHE1 with impaired COMT) to its downstream tissue consequence — catechol estrogen oxidation to reactive quinones is the documented mechanistic link.

---

Common clinical patterns in DUTCH results and their treatment implications

High cortisol with estrogen dominance pattern

The most frequently encountered combination in perimenopausal patients: elevated or frozen cortisol driving progesterone depletion via pregnenolone steal, with a resulting unfavorable 2/16 ratio and often elevated 4-OHE1.

The mechanism: when cortisol demand is chronically elevated, the shared precursor pregnenolone is preferentially routed toward cortisol synthesis. Progesterone production falls. Lower progesterone against a backdrop of persistent estrogen production creates relative estrogen dominance — irregular or heavy cycles, breast tenderness, perimenstrual mood disruption, and bloating — even if serum estradiol is not dramatically elevated.

Interpretation priority: Address cortisol first. Starting progesterone supplementation before the cortisol driver is identified produces a partial response at best. The root cause is the stress axis, not the sex hormone axis.

Flat cortisol with low DHEA (burnout pattern)

Low cortisol across all four time points, depleted DHEA-S, and a high cortisol:DHEA-S ratio that has inverted (now low cortisol with disproportionately low DHEA-S) is the late-stage HPA depletion picture.

Clinically: exhaustion from waking, no morning energy arc, poor exercise tolerance, flat mood, and a history of sustained output — often caregiving, clinical practice, or chronic illness — over 12 to 36 months.

It is a pattern practitioners in functional medicine communities describe with regularity: complex lab-heavy mornings deplete clinical capacity for afternoon patients, and the cognitive cost compounds across a high-volume caseload. This is precisely where an interpretive framework — applied consistently — reduces cognitive load rather than adding to it.

Protocol priorities: Remove stimulants. KSM-66 ashwagandha 600mg/day, rhodiola rosea AM, B-complex with Vitamin C, adrenal glandular support initially. Do not supplement DHEA until cortisol pattern begins stabilizing — exogenous DHEA without addressing root cause provides transient effect.

Impaired estrogen methylation (elevated 4-OH estrogen metabolites)

Elevated 4-OHE1 with a low 2-MeOE1/2-OHE1 ratio is the pattern that changes treatment priority most significantly — and the one most often missed when practitioners interpret DUTCH results in report order rather than mechanistic sequence.

The 4-OH catechol estrogen can undergo oxidation to reactive quinones when COMT methylation is inadequate. This creates a genotoxic risk profile that is separate from symptomatic estrogen dominance. A patient can have relatively normal overall estrogen levels and a symptomatic presentation that looks mild, with a 4-OHE1 elevation that warrants aggressive methylation support.

Methylation bottleneck protocol: Methylcobalamin + L-5-MTHF (not folinic acid — the active form matters); riboflavin (B2) as an often-overlooked direct COMT cofactor; magnesium glycinate; P-5-P if xanthurenic acid is elevated on OAT. DIM 200–400mg/day to shift CYP1A1/1B1 balance and reduce 4-OH production at Phase 1. Add DIM only after methylation support is in place — increasing 2-OH production without adequate COMT activity to methylate it does not reduce the genotoxic burden.

---

Cross-referencing DUTCH findings with GI-MAP and other functional labs

DUTCH findings do not exist in isolation. Three cross-lab relationships alter interpretation regularly:

DUTCH + GI-MAP: Intestinal dysbiosis elevates beta-glucuronidase activity, which deconjugates estrogen metabolites in the gut, allowing them to re-enter enterohepatic circulation in their active form. Elevated estrogen metabolites on DUTCH in a patient with elevated beta-glucuronidase on GI-MAP interpretive guide creates a compound estrogen burden that neither test fully explains alone. Treating estrogen metabolism without addressing the GI driver produces a partial response.

DUTCH + Thyroid Panel: The DUTCH test does not measure thyroid hormones, but elevated cortisol suppresses T4→T3 conversion via 5'-deiodinase inhibition. A patient with normal TSH, borderline T4, and low T3 on serum who also has elevated DUTCH cortisol has a treatable driver for the thyroid pattern. Treating the adrenal picture often improves T3 conversion without thyroid-targeted intervention.

DUTCH + OAT (if ordered as a separate panel): When DUTCH Complete OAT markers are borderline or the clinical picture suggests a more complex neuro-metabolic picture, a standalone Great Plains or Mosaic OAT provides additional mitochondrial markers (succinic acid, malic acid, citric acid) and extended gut dysbiosis indicators. The DUTCH OAT section is a screener; the standalone OAT is the deeper investigation.

---

From DUTCH interpretation to clinical note: what efficient documentation looks like

A complete DUTCH interpretation note needs to capture: cortisol pattern diagnosis and clinical significance, DHEA-S and the cortisol:DHEA-S ratio, estrogen metabolite pathway summary (2/16 ratio, 4-OHE1 status, COMT throughput), progesterone and androgen assessment, OAT findings with their cross-marker context, and the root cause narrative that connects these systems into a treatment sequence.

Interpreting and documenting a DUTCH Complete commonly takes 30–60 minutes per patient. The report is dense — nearly 50 markers across six categories — and the interpretive work requires translating marker relationships into a clinical narrative, not just reading individual values. The challenge of efficiently synthesizing a full DUTCH or GI-MAP panel into a clinical note is a recurring theme in functional medicine practitioner communities, and it reflects a real time constraint, not a skill gap.

The documentation bottleneck is the root cause behind delayed note completion, incomplete protocol handoffs to patients, and the cognitive depletion that accumulates across a high-volume interpretive caseload.

---

Use Hans to cut DUTCH interpretation time in half

Hans was built for AI for functional medicine practitioners who need a faster path through complex multi-system lab panels. It reads DUTCH Complete results across all sections — generating structured clinical summaries, surfacing cross-marker patterns (estrogen methylation impairment, cortisol:DHEA-S imbalance, OAT-cortisol interactions), and producing documentation-ready interpretation frameworks calibrated to functional medicine clinical standards.

Hans does not make clinical decisions. It surfaces the interpretive data and pattern relationships so that practitioners can apply clinical judgment faster — without rebuilding the interpretive framework from scratch on each case.

Practitioners using Hans report measurable reductions in functional lab interpretation time.

See how Hans handles DUTCH interpretation → Request access

---

Peter Kozlowski, MD

Reviewed by: Andrew Le, MD